Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • cancer

    Tag: cancer

    You Searched For "cancer"
    Zydus, XOMA enter into licensing agreement for  IL-2-Based Immuno-Oncology Therapy

    Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy

    Medical Dialogues Bureau11 March 2020 3:30 AM GMT
    Ahmedabad, Emeryville: Zydus Cadila and XOMA Corporation have announced they have entered into a licensing agreement to advance an IL-2-based...
    AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial

    AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial

    Medical Dialogues Bureau10 March 2020 4:00 AM GMT
    USA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not...
    Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

    Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

    Medical Dialogues Bureau25 Nov 2019 3:30 AM GMT
    Median overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
    AstraZeneca leukemia drug Calquence gets USFDA okay

    AstraZeneca leukemia drug Calquence gets USFDA okay

    Medical Dialogues Bureau24 Nov 2019 4:30 AM GMT
    New Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
    FIRST: Roche wins DCGI nod for Atezolizumab to treat small-cell lung cancer

    FIRST: Roche wins DCGI nod for Atezolizumab to treat small-cell lung cancer

    Medical Dialogues Bureau22 Nov 2019 6:55 AM GMT
    "Atezolizumab is the first cancer immunotherapy to receive approval from DCGI in India for the first-line treatment of extensive-stage small-cell lung...
    BeiGene gets USFDA approval for lymphoma drug Brukinsa

    BeiGene gets USFDA approval for lymphoma drug Brukinsa

    Medical Dialogues Bureau17 Nov 2019 3:50 AM GMT
    BeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
    Aurobindo Pharma USA recalls heartburn drug Ranitidine over cancer causing impurities

    Aurobindo Pharma USA recalls heartburn drug Ranitidine over cancer causing impurities

    Medical Dialogues Bureau10 Nov 2019 4:15 AM GMT
    Aurobindo Pharma is second city-based drug company that has initiated the voluntary recall after the FDA announced an investigation into the reported...
    Shilpa Medicare gets USFDA approval for generic equivalent of cancer drug TARCEVA

    Shilpa Medicare gets USFDA approval for generic equivalent of cancer drug TARCEVA

    Farhat Nasim8 Nov 2019 4:30 AM GMT
    Erlotinib Tablets, 25 mg, 100 mg, and 150 mg is a generic equivalent of reference listed drug (RLD) TARCEVA used in the treatment of patients with...
    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    Medical Dialogues Bureau7 Nov 2019 10:50 AM GMT
    Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug...
    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Medical Dialogues Bureau3 Nov 2019 3:30 AM GMT
    Bristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
    Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA

    Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA

    Medical Dialogues Bureau2 Nov 2019 4:00 AM GMT
    Zantac sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible...
    Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

    Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

    Medical Dialogues Bureau2 Nov 2019 3:30 AM GMT
    Out of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok